Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis
Intravenous immunoglobulin (IVIg) has been proven beneficial in myasthenic crisis, but their role as maintenance therapy is unclear. The aim of this study was to determine if maintenance therapy with low-dose IVIg improves clinical outcomes and may be used as a steroid-sparing agent in myasthenia gravis (MG). Long-term treatment response to IVIg was assessed by improvement in the Myasthenia Gravis Foundation of America (MGFA) clinical classification scale as the primary endpoint. Low-dose IVIg
